LIPO - Lipella Pharmaceuticals Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

LIPO

LIPELLA PHARMACEUTICALS INC.

OTC

$0.00

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$1.85 K

52w High$0.64

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume160.09K

Shares Out.4.62M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jonathan Kaufman

COMPENSATION 2026

Salary$204,133

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$323,383

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 19, 2022

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$2.00

Target Low$2.00

Target Median$2.00

Target Consensus$2.00

UPCOMING EARNINGS

DateSep 2, 2026

DayWednesday

Rev. Est.$146.00K

SEP

WED

SPLIT RECORD

DATE	TYPE	RATIO
2024-11-08	Reverse	1:8

PRICE

$0.00 ▲ UP 0.00% (+$0.00)

OVERLAYS

About Lipella Pharmaceuticals Inc.

https://www.lipella.com ↗

Lipella Pharmaceuticals Inc. is a clinical-stage biotech company developing reformulated generic drugs like LP-10 and LP-310 for conditions such as hemorrhagic cystitis and oral lichen planus, based in Pittsburgh.

INDUSTRY

Biotechnology

A PRODUCT LIPELLA PHARMACEUTICALS INC. IS KNOWN FOR

LP-10 (liposomal tacrolimus oral rinse)

LP-10 is a proprietary tacrolimus oral rinse in development for oral lichen planus, with Phase 2a results showing significant safety and efficacy, potentially making it the first-in-class FDA-approved treatment for this underserved condition.